European Commission approves Evrenzoto treat adult patients with symptomatic anemia associated with chronic kidney disease – Astellas + FibroGen Inc.

Astellas Pharma Inc.and FibroGen, Inc. announced that the European Commission (EC) has approved Evrenzo (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney diseases (CKD). CKD impacts one in 10 people globally, of whom one in five are affected by anemia. Anemia of CKD is often untreated or not treated to target, and is associated […]